Sunday 11 October 2026 Export all RLYB data to Excel Powerpack

Rallybio Corporation

RLYB Healthcare Biotechnology

In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

17.02 0.03 +0.18%
Market cap
$90.2M
P/E
2.1×
Fwd P/E
−3.5×
Dividend yield
—
F-score
n/a
Altman Z
−3.12
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— 0.00 0.00 0.00

+8 more quarters

P/S ratio
— 59.48 36.02 33.34
P/FCF ratio
— 0.00 0.00 0.00
P/Operating CF
— (6.40) (6.61) (3.43)
P/B ratio
— 1.02 0.53 0.36
Price to Tangible BV
— 1.02 0.53 0.36
EV/Sales
— 4.94 (27.77) (54.67)
EV/EBITDA
— 0.00 0.71 0.95
EV/Operating CF
— (0.15) 0.80 1.05
EV/FCF
— (0.15) 0.80 1.05
Quick Ratio
26.03 11.30 12.96 13.13
Current Ratio
27.26 12.92 14.50 14.74
Net Debt/EBITDA
16.42 5.33 8.41 8.47
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.02 0.01 0.01
Operating CF/Net income
1.05 0.96 0.80 (0.41)
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 1,354.25% 1,646.40% 1,954.25%
Selling, General and Administrative Expense of Revenue
0.00% 2,865.09% 1,341.89% 1,412.26%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 289.15% 348.65% 493.87%
Graham Net Nets
— 0.97 1.84 2.76
Graham Number
— 0.00 0.00 0.00
Earnings Yield
— (15.17%) (28.80%) (64.16%)
Free Cash Flow Yield
— (54.12%) (96.55%) (155.86%)
Revenue per Share
0.00 0.04 0.04 0.04
Operating CF per Share
8.06 (1.40) (0.83) (1.16)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
8.06 (1.40) (0.83) (1.16)
Cash per Share
16.29 8.23 9.72 10.53
Shareholders Equity per Share
16.58 8.84 10.29 11.19
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
16.58 8.84 10.29 11.19
Free Cash Flow
45.92 (7.98) (4.68) (6.55)
Working Capital
93.69 49.35 57.03 62.11
Net Current Asset Value
93.69 49.30 56.95 62.00
EV/EBIT
— 0.00 0.72 0.96
Capex to Sales
— 0.00 0.00 0.00
Price to Operating Income
— 0.00 0.00 0.00
Other line items
Average Payables
0.48 0.67 0.20 0.43
Average Assets
74.53 56.23 65.18 73.33
Average Common Equity
70.23 52.18 59.81 66.93

Fold the line items

Columns are period end dates